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In human cancers, giant cadherin FAT1 may function both, as an 
oncogene and a tumor suppressor. Here, we investigated the expres-
sion and function of FAT1 in hepatocellular carcinoma (HCC). 
FAT1 expression was increased in human HCC cell lines and tis-
sues compared with primary human hepatocytes and non-tumorous 
liver tissue as assessed by quantitative PCR and western blot analy-
sis. Combined immunohistochemical and tissue microarray analy-
sis showed a significant correlation of FAT1 expression with tumor 
stage and proliferation. Suppression of FAT1 expression by short 
hairpin RNA impaired proliferation and migration as well as apop-
tosis resistance of HCC cells in vitro. In nude mice, tumors formed 
by FAT1-suppressed HCC cells showed a delayed onset and more 
apoptosis compared with tumors of control cells. Both hepatocyte 
growth factor and hypoxia-mediated hypoxia-inducible factor 1 
alpha activation were identified as strong inducers of FAT1 in HCC. 
Moreover, demethylating agents induced FAT1 expression in HCC 
cells. Hypoxia lead to reduced levels of the methyl group donor 
S-adenosyl-l-methionine (SAM) and hypoxia-induced FAT1 expres-
sion was inhibited by SAM supplementation in HCC cells. Together, 
these findings indicate that FAT1 expression in HCC is regulated 
via promotor methylation. FAT1 appears as relevant mediator of 
hypoxia and growth receptor signaling to critical tumorigenic path-
ways in HCC. This knowledge may facilitate the rational design of 
novel therapeutics against this highly aggressive malignancy.
Introduction
Cadherins are major contributors to cell–cell adhesion in epithelial 
tissues and play a critical role in morphogenetic and differentiation 
processes during development, and in maintaining integrity and home-
ostasis in adult tissues (1). Several cadherins have been identified as 
potential tumor suppressors or oncogenic proteins depending on the 
type of cadherin and the type of cancer (2). The cadherin subfamily 
FAT is characterized by large extracellular domains containing 34 cad-
herin motifs, making it the largest of all cadherin molecules (3). The 
first identified member of this family, Drosophila Fat, has been shown 
to be involved in cell proliferation and survival as well as cellular 
polarity (4). FAT1 was identified as the first Fat-like protein in verte-
brates (5). Mice lacking FAT1 exhibit perinatal lethality with defects 
in kidney and brain (6). Transcript variants derived from alternative 
splicing exist, but their differential function just begins to be elucidated 
(7). Moreover, FAT1’s mechanisms of action in normal and diseased 
tissues are incompletely understood (3,8). In cancer, FAT1 appears to 
act as tumor suppressive or oncogenic in a context-dependent manner 
(8). Frequent loss of heterozygosity of FAT1 has been described in 
oral squamous cell carcinomas and astrocytic tumors (9,10). In chol-
angiocarcinoma, immunohistochemistry demonstrated reduced FAT1 
expression at the normal membranous location (11) and FAT1 is pref-
erentially downregulated in invasive breast cancer (12). In contrast, 
FAT1 is upregulated in leukemia and prognosis of precursor B-cell 
acute lymphoblastic leukemia patients with FAT1 upregulation is poor 
(13). Functional in vitro studies revealed that FAT1 acts as a regulator 
of oncogenic pathways in glioma cell lines (14).
Here, we aimed to assess the expression and function of FAT1 
in hepatocellular carcinoma (HCC), which is the fifth most com-
mon cancer worldwide and the third most common cause of cancer 
mortality (15). HCC is strongly associated with liver fibrosis, with 
90% of HCC cases arising in cirrhotic livers (16). Recently, we have 
shown increased FAT1 expression during liver fibrogenesis and iden-
tified activated hepatic stellate cells (HSCs) as the cellular source 
of increased FAT1 expression in diseased livers (17). In the present 
study, we describe a novel mechanism by which activated HSCs 
induce FAT1 expression in HCC cells and identify FAT1 as tumor 
promoter in this highly aggressive hepatic cancer.
Materials and methods
Cells and cell culture
The HCC cell lines HepG2 (ATCC HB-8065), PLC (ATCC CRL-8024) and 
Hep3B (ATCC HB-8064) were cultured as described (18). Primary human 
hepatocytes (PHH) and HSCs were isolated and cultured as described (18–20). 
In vitro activation of HSCs was achieved by cell culture on uncoated tissue cul-
ture dishes (20). Collection of conditioned medium (CM) from activated HSCs 
and control medium was done as described (18). For individual experiments, 
CM was preincubated with anti-human hepatocyte growth factor (HGF) or 
isotope control antibodies (100 μg/ml; all from R&D Systems, Wiesbaden, 
Germany). Recombinant HGF was purchased from R&D Systems.
Hypoxia was induced by exposure to 1% O2 or incubation with 2,2-dipyri-
dyl (DP) (100 µmol/l; Sigma–Aldrich, Deisenhofen, Germany) for the indi-
cated periods of time. For pharmaceutical inhibition of hypoxia-inducible 
factor (HIF)-1 activity, cells were incubated with 10 nmol/l of echinomycin 
(Alexis Biochemicals, Lörrach, Germany). Protein synthesis was inhibited by 
cycloheximide and for demethylation cells were stimulated with either 5-aza-
2′deoxycytidine (Aza), adenosine-2′,3′-dialdehyde (Adox) or S-adenosyl-l-
methionine (SAM) (all from Sigma–Aldrich).
Human tissues and HCC tissue microarray
Paired HCC and non-neoplastic liver tissues were obtained from HCC 
patients undergoing surgical resection. Tissue samples were immediately 
snap-frozen and stored at −80°C until analysis. A  tissue microarray (TMA) 
of paraffin-embedded HCC samples was constructed as described (18,21–23). 
Clinicopathological patient characteristics are summarized in Table I.
Tissue samples from liver resections for cell isolation and expression analy-
ses were obtained from patients undergoing partial hepatectomy. Experimental 
procedures were performed according to the guidelines of the charitable state 
controlled foundation HTCR (Human Tissue and Cell Research), with the 
informed patient’s written consent approved by the local ethical committee of 
the University of Regensburg (24). All experiments involving human tissues 
and cells have been carried out in accordance with The Code of Ethics of the 
World Medical Association (Declaration of Helsinki).
Transfection of HCC cell lines
Applying the Lipofectamine plus method (Invitrogen, Carlsbad, CA) cells 
were transfected with a dominant-negative HIF 1 alpha (HIF1α) construct 
(25). FAT1-suppressed cell clones were established by stable transfection of 
PLC cells with a FAT1 short hairpin RNA (shRNA) plasmid. The FAT1 shRNA 
plasmid was prepared as shown previously (26). Plasmids were cotransfected 
with pcDNA3 (Invitrogen), containing the selectable marker for neomycin 
resistance. Controls received pcDNA3 alone. One day after transfection, cells 
Abbreviations: CM, conditioned medium; DP, dipyridyl; HCC, hepatocel-
lular carcinoma; HGF, hepatocyte growth factor; HIF1α, hypoxia-inducible 
factor 1 alpha; HSC, hepatic stellate cell; MAZ, Myc-associated zinc finger 
protein; mRNA, messenger RNA; PHH, primary human hepatocytes; SAM, 
S-adenosyl-l-methionine; shRNA, short hairpin RNA; siRNA, small interfer-
ing RNA; TMA, tissue microarray; VEGF, vascular endothelial growth factor.
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were placed in selection medium containing 200 μg/ml G418 (Sigma). After 
25 days of selection, individual G418-resistant colonies were subcloned.
AP-1 reporter gene assay
Cells were transfected with a AP1 luc plasmid (Stratagene, La Jolla, CA) using 
Lipofectamine Plus reagent (Invitrogen, Karlsruhe, Germany) as described 
(27). For normalization of transfection efficiency, cells were contransfected 
with pRL-TK plasmid resulting in a renilla luciferase acitivity (Promega, 
Mannheim, Germany), and after 24 h cells were lysed and the luciferase activi-
ties were measured as described (27).
Expression analysis
Isolation of total cellular RNA from cultured cells and tissues and reverse tran-
scription were performed as described previously. Quantitative real-time PCR was 
performed on a LightCycler (Roche, Mannheim, Germany) using the following 
sets of primers: FAT1 (for: 5′-GTG TTT GTT CTC TGC CGT AAG-3′; rev: 5′-
TAG GCT TCT GGA TGG AGT CG-3′), E-CAD (for: 5′-ATC CTC CGA TCT 
TCA ATC CCA CCA C-3′; rev: 5′-GTA CCA CAT TCG TCA CTG CTA CGT 
G-3′), MAT2A (for: 5′-CCA CGA GGC GTT CAT CGA GG-3′; rev: 5′-AAG 
TCT TGT AGT CAA AAC CT-3′). Vascular endothelial growth factor (VEGF), 
SNAIL, Myc-associated zinc finger protein (MAZ) and PDCD4 messenger RNA 
(mRNA) expression analysis were performed using QuantiTect Primer Assay 
according to the manufacturer’s instructions (Qiagen, Hilden, Germany).
Protein analysis
Protein extraction and western blotting were performed as described (18) using 
the following antibodies: anti-FAT1 (1:1000; Atlas Antibodies AB, Stockholm, 
Sweden), anti-HIF1α (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and 
anti-β-actin (1:20 000; Sigma).
For immunohistochemistry, hematoxylin and eosin staining, and terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling staining, standard 
5 μm sections of formalin-fixed and paraffin-embedded tissue blocks were used.
Immunohistochemical staining was performed using the following anti-
bodies: anti-FAT1 (1:50; Atlas Antibodies AB), Ki67 (MIB1, 1:50; Abcam, 
Cambridge, UK), Caspase 3 (1:150; Epitomics, Burlingame, CA) and anti-c-
Jun (1:100, #9165; Cell Signaling Technology), as described (28). Terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling staining was 
performed as described (21).
For analysis of the TMA, positivity for FAT1 was defined as detectable 
membranous staining, whereas cases designated as FAT1 negative were devoid 
of FAT1 staining.
S-Adenosyl-l-methionine extraction and analysis
For analysis of S-adenosyl-l-methionine (SAM) in cell culture medium, 
cells were cultured in serum-free medium for 24 h. Subsequently, medium 
was collected, centrifuged, and the supernatant was snap-frozen and stored 
at −80°C. SAM analysis was performed with liquid chromatography-electro-
spray ionization-tandem mass spectrometry as described (29).
Analysis of proliferation, migration and resistance against sorafenib 
treatment
Cell proliferation was measured using the XTT (2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay (Roche) as described 
(22). Cell migration was quantified using the xCELLigence system according 
to the instructions of the supplier (Roche Applied Science).
To analyze the resistance against sorafenib treatment, cells were incubated 
with different doses of sorafenib (3, 10, 30 µM) or vehicle (dimethyl sulfoxide) 
for 48 h followed by analysis of XTT activity.
Analysis of apoptosis
For detection of apoptosis, cells were stained simultaneously with FITC-
conjugated Annexin V and propidium iodide (both from Pharmingen, 
Germany) and analyzed by flow cytometry (20). Further, the Caspase-Glo 3/7 
Assay (Promega, Madison, WI) was used to analyze caspase-3/7 activity (30).
Tumor cell inoculation and measurement of tumor growth in NMRI (nu/nu)  
mice
A model of inoculation of tumor cells into NMRI (nu/nu) mice to monitor 
tumor growth in vivo was performed as described (21,22) following the insti-
tutional (University of Regensburg) and National Guidelines for the Care and 
Use of Animals. For ethical reasons, mice were killed upon observation of the 
first signs of tumor ulceration. Tumors were excised, snap-frozen and stored in 
liquid nitrogen for subsequent analysis.
Statistical analysis
Results are expressed as mean ± standard error (range) or percent. Comparison 
between groups was made using the Student’s unpaired t-test. A  P value < 
0.05 was considered statistically significant. Contingency table analysis and 
the two-sided Fisher’s exact test were used to study the statistical association 
between clinicopathological and immunohistochemical variables. All calcu-
lations were performed by using the GraphPad Prism Software (GraphPad 
Software, San Diego, CA) or SPSS (SPSS, Chicago, IL).
Results
FAT1 expression in HCC
Initially, we analyzed FAT1 mRNA expression in three different HCC 
cell lines (HepG2, PLC and Hep3B) and PHH by quantitative real-
time PCR and western blot analysis. In all three HCC cell lines FAT1 
Table I. FAT1 immunoreactivity (IR) in HCC tissue of 112 patients in relation to clinicopathological characteristics and proliferation rate
Variable Categorization n % FAT1 IR weak FAT1 IR strong P*
Clinicopathological characteristics
Age at diagnosis
<60 years 40 35.7 13 27 1.000
≥60 years 72 64.3 23 49
Gender
Female 17 15.2 3 14 0.259
Male 95 84.8 33 62
Tumor stage
pT1 42 37.5 17 25 0.042
pT2 27 24.1 12 15
pT3 38 33.9 6 32
pT4 3 2.7 1 2
nd 2 1.8 0 2
Histological grade
G1 42 37.5 14 28 1.000
G2 59 52.7 19 40
G3 11 9.8 3 8
Tumor size
≤5 cm 60 53.6 19 41 0.921
>5 cm 36 32.1 11 25
nd 16 14.3 6 10
Proliferation rate (MIB1 index)
≤5% 46 41.1 20 26 0.040
>5% 66 58.9 16 50
IR, immunoreactivity; nd, no data available.
*Fisher’s exact test (two sided); boldface representing P values < 0.05.
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mRNA and protein expression were significantly increased compared 
with PHH (Figure 1A and B). Comparison of human HCC tissue and 
corresponding non-tumorous liver tissue of 14 patients confirmed a 
strong upregulation of FAT1 mRNA in cancerous tissue (Figure 1C).
To evaluate the functional effects of FAT1 upregulation in HCC in 
vivo, we analyzed FAT1 protein expression in a series of 112 human 
HCC tissues, applying immunohistochemistry and TMA technology. 
Membranous FAT1 staining intensity varied significantly among indi-
vidual patients. For descriptive data analysis, HCC were scored as 
exhibiting either strong or weak immunosignal (representative exam-
ples are depicted in Figure 1D), and immunohistochemical results were 
correlated with clinicopathological characteristics (Table I). Strong 
membranous FAT1 staining was significantly associated with higher 
tumor stage (P = 0.042) and proliferation rate (Ki-67 labelling index; 
P = 0.040), respectively. No correlation was found between FAT1 
expression and tumor grading and tumor size or patients’ age and sex.
Inhibition of FAT1 expression in HCC cells
To gain insight into the functional role of increased FAT1 in HCC, we 
inhibited FAT1 expression in the HCC cell line PLC by stable transfection 
with a shRNA expression vector containing the sequence of FAT1 small 
interfering RNA (siRNA) (FAT1 shRNA#1, FAT1 shRNA#2). PLC cells 
transfected with the empty vector served as control. Quantitative reverse 
transcription–polymerase chain reaction and western blot analysis 
revealed a strong downregulation of FAT1 expression in FAT1 shRNA 
compared with control cell clones (Figure 2A). FAT1-suppressed HCC 
cells showed normal histological morphology (Figure 2B), and also the 
expression of E-Cadherin (E-Cad) and Snail, two markers of epithelial-
mesenchymal transition, did not differ significantly compared with con-
trol cells (Supplementary Figure 1, available at Carcinogenesis Online).
To characterize the role of FAT1 in HCC cells, we performed func-
tional in vitro assays with FAT1-suppressed cells in comparison with 
control cells. HCC cells with suppressed FAT1 expression grew sig-
nificantly slower (Figure  2C). Migration assays demonstrated that 
suppression of FAT1 inhibited the migratory potential of HCC cells 
(Figure 2D). Moreover, serum starvation induced significantly higher 
caspase-3/7 activation (Figure 2E) and a higher apoptosis rate in HCC 
cells with suppressed FAT1 expression compared with control cells 
(Figure 2F). We also analyzed the resistance of FAT1 suppressed and 
control cells against sorafenib treatment in vitro but did not observe 
significant differences (Figure 2G).
In search for the underlying mechanism of FAT1 on proliferation, 
migration and apoptosis resistance in HCC cells, we analyzed expres-
sion of tumor suppressor gene programmed cell death 4 (PDCD4) 
because a recent study by Dikshit et al. (14) identified FAT1 as inhibi-
tor of this tumor suppressor gene in glioblastoma multiforme. Also 
in HCC PDCD4 was identified as tumor suppressor gene inducing 
apoptosis and inhibiting their metastatic potential (31,32). However, 
PDCD4 expression levels did not differ significantly between FAT1-
suppressed and control cells (Supplementary Figure  2A, available 
at Carcinogenesis Online). Moreover, Dikshit et al. discovered that 
FAT1 inhibited c-Jun phosphorylation and herewith led to the attenu-
ation of activator protein-1 (AP-1) in glioblastoma. AP-1 is a critical 
regulator of tumorigenicity of HCC cells (33,34) but reporter gene 
analysis showed similar activity in HCC cells with and without FAT1 
suppression (Supplementary Figure 2B, available at Carcinogenesis 
Online).
Tumorigenicity of FAT1-suppressed HCC cells in vivo
To test the effect of FAT1 on tumor growth in vivo, HCC cells sta-
bly suppressing FAT1 and control cells were injected subcutaneously 
into nude mice. Tumors derived from FAT1-suppressing HCC cell 
clones showed delayed tumor onset compared with tumors derived 
from mock-transfected control cells (Figure 3A). Expression analy-
sis revealed preservation of FAT1 mRNA suppression in tumors 
(Figure 3B). Terminal deoxynucleotidyl transferase dUTP nick-end 
labeling staining showed only few apoptotic cells in control-trans-
fected HCC-derived tumors, whereas the FAT1-suppressing tumors 
displayed large apoptotic areas (Figure 3C).
Regulation of FAT1 expression in HCC cells
Activated HSCs form and transduce the HCC stroma (35). Previously, 
we have shown that HSCs secrete factors by which they promote 
growth and migration of HCC cells in vitro (36). This prompted us 
to examine the effect of CM from activated HSCs on FAT1 mRNA 
expression in HCC cells. Quantitative reverse transcription–poly-
merase chain reaction showed increased FAT1 mRNA expression 
in HCC cells after incubation with CM from HSCs (Figure 4A). In 
search for the factors in CM of HSCs responsible for FAT1 upregula-
tion in HCC cells we focused on HGF, which is known to promote 
hepatocancerogenesis.
Fig. 1. FAT1 expression in HCC. (A) mRNA and (B) protein expression of FAT1 in HCC cell lines (HepG2, PLC and Hep3B) and PHH. (C) FAT1 
mRNA expression in tumor tissue of 14 HCC patients (T) and in corresponding non-neoplastic liver (NT). (D) Examples of weak (I) and strong (II) 
immunohistochemical FAT1 staining of human HCC tissues. (*P < 0.05 compared with PHH or NT).
1409
D.Valletta et al.
Stimulation of HCC cells with HGF (50 ng/ml) induced a signifi-
cant upregulation of FAT1 mRNA and protein expression (Figure 4B). 
Preincubation of CM from activated HSCs with anti-HGF antibodies 
completely abrogated the stimulating effect on FAT1 (Figure  4C). 
Together, these data indicate that activated HSCs induce FAT1 in 
HCC cells via HGF secretion.
Fig. 2. Inhibition of FAT1 expression in HCC cells. (A) FAT1 mRNA and protein expression in HCC cell clones stably transfected with FAT1 shRNA (FAT1 shRNA#1; 
FAT1 shRNA#2) or control shRNA (ctrl) (*P < 0.05 compared with ctrl). (B) Morphology of FAT1-suppressed and control cells. (C) Doubling time and (D) migration 
of FAT1-suppressed and control cells (*P < 0.05 compared with ctrl). (E) Analysis of caspase 3/7 activity in FAT1-suppressed and control cells after serum deprivation 
(*P < 0.05 compared with ctrl). (F) Assessment of apoptosis by flow cytometry applying annexin V and propidium iodide (PI) staining. Depicted is the mean percentage 
of total apoptotic cells from three independent experiments (*P < 0.05 compared with ctrl). (G) Analysis of XTT activity in FAT1-suppressed and control cells after 
incubation with sorafenib (3, 10, 30 µM) in relation to control cells without sorafenib treatment (*P < 0.05 compared with cells without sorafenib treatment).
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To further elucidate the HGF-induced transcriptional regulation of 
FAT1 we focused on HIF1α, because it has been shown that HGF 
enhances the activity of this transcription factor in HCC cells (37). 
Further, HIF1α plays a critical role in HCC development and pro-
gression (38). HGF-induced FAT1 expression was completely inhib-
ited by echinomycin, a pharmaceutical inhibitor of HIF1α activity 
(Figure 4D). HIF1α is also an important mediator of hypoxic adap-
tion of tumor cells (39), and accordingly, induction of hypoxia by 
incubation with the chemical inducer DP caused a significant upreg-
ulation of FAT1 (Figure  4E and F). Western blot analysis demon-
strated stabilization of HIF1α in DP-treated cells (Figure 4F). FAT1 
upregulation under DP-induced hypoxia was strongly repressed by 
echinomycin (Figure 4G). In line with this finding, transient transfec-
tion with a dominant-negative variant of HIF1α (40) led to diminished 
DP-induced FAT1 expression (Figure 4H). Together, these data indi-
cate HIF1α as critical regulator of HGF- and hypoxia-induced FAT1 
expression in HCC cells.
Mechanisms of FAT1 regulation in HCC
However, in silico analysis of the FAT1 promoter did not show an 
HIF1 binding site [Tess (http://www.cbil.upenn.edu/cgi-bin/tess/
tess?RQ=WELCOME) and Genomatix software; data not shown]. 
Furthermore, costimulation with cycloheximide, an inhibitor of 
protein synthesis, abolished HGF- and hypoxia-induced upregu-
lation of FAT1 mRNA expression in HCC cells (Figure  5A and 
Supplementary Figure 2, available at Carcinogenesis Online). These 
data indicated that hypoxia and HIF1α, respectively, did not directly 
induce FAT1 expression at the transcriptional level. Still, hypoxia 
can cause epigenetic modifications as demethylation (41), and it has 
been shown that the methylation status of the FAT1 CpG island in 
squamous cell carcinomas correlated negatively with its expression 
(10). Here, we found that incubation with 5-aza-2′deoxycytidine 
(Aza) and adenosine-2′,3′-dialdehyde (Adox) both inhibitors of 
DNA methylation, caused a dose-dependent upregulation of FAT1 
expression in HCC cells (Figure  5B). Most recently, it has been 
shown that hypoxia-induced DNA demethylation in HCC is caused 
through activation of HIF1α and transcriptional upregulation of 
methionine adenosyltransferase II, alpha (MAT2A) (42). MAT is 
the critical enzyme for the reaction of methionine and adenosine 
triphosphate to SAM. There are two genes (MAT1A, MAT2A) for 
two homologous catalytic MAT subunits (MATI, MATII). Although 
MAT1A is mainly expressed in healthy liver, a switch from MAT1A 
to MAT2A takes place during the progression of HCC (43). This 
leads to reduced SAM levels due to the lower enzymatic activity 
of MATII compared with MATI (44). Also in the present study 
we observed reduced SAM levels in the supernatant of HCC cells 
after chemical induction of hypoxia (Figure  5C). Replenishment 
of SAM in culture medium of HCC cells dose-dependently inhib-
ited hypoxia-induced FAT1 expression (Figure  5D). These find-
ings indicate that hypoxia-induced FAT1 expression in HCC cells 
is mediated via MAT2A-mediated SAM depletion and subsequent 
demethylation of the FAT1 promotor.
To verify these findings in vivo we assessed FAT1 and VEGF 
expression in 25 human HCC specimens by quantitative reverse tran-
scription–polymerase chain reaction. VEGF is highly regulated by 
HIF1α in HCC (45), and notably, we found a significant correlation 
between VEGF and FAT1 expression in HCC tissues (Figure  5E). 
Furthermore, FAT1 and MAT2A expression showed a significant cor-
relation in HCC tissues (Figure 5F). Together, these data suggest that 
also in vivo hypoxia is a critical regulator of FAT1 expression in HCC. 
This effect seems to be at least in part mediated via enhanced MAT2A 
expression and subsequent depletion of SAM levels leading to dem-
ethylation of the FAT1 promoter.
In search for the molecular mechanisms responsible for the sig-
nificantly enhanced basal FAT1 expression levels in HCC cells 
compared with hepatocytes, we focused on MAZ because in silico 
analysis (Genomatix software) revealed a MAZ binding site located 
242 bp upstream of the transcriptional start site of the human FAT1 
gene. Furthermore, we have shown previously that MAZ expression in 
HCC cells is markedly enhanced compared with PHH (18). Transient 
Fig. 3. Tumorigenicity of FAT1-suppressed HCC cells in vivo. (A) Onset of tumors derived from FAT1-suppressed or control cells implanted in nude 
mice. (B) FAT1 mRNA expression in tumors derived from FAT1-suppressed or control cells. (C) Analysis for apoptotic cells in tumor tissue using terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining (green) and 4′,6-diamidino-2-phenylindole (DAPI) staining for nuclei (blue) 
(*P < 0.05 compared with ctrl).
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transfection with two different MAZ siRNAs significantly inhibited 
MAZ mRNA expression in Hep3B cells compared with HCC cells 
transfected with control siRNA (ctrl siRNA) and non-transfected con-
trol cells (ctrl) (Figure 5G). Notably, MAZ suppression caused a sig-
nificant but not complete downregulation of FAT1 expression in HCC 
cells (Figure 5H).
In summary, these data indicate that constitutively high FAT1 
mRNA expression in HCC cells under normoxic conditions is at least 
in part dependent on the transcription factor MAZ. FAT1 mRNA 
expression is further increased via HSC-secreted HGF or hypoxia-
induced HIF-1 activation in HCC.
Discussion
The giant cadherin FAT1 is one of four vertebrate orthologues of the 
Drosophila tumor suppressor fat. The specific function of FAT1 in can-
cer development and progression is still under investigation. There are 
contrasting studies about the role of FAT1 in human cancers, pointing 
toward a dual role of FAT1 as both an oncogene as well as a tumor 
suppressor (9–13,46). Here, we found increased FAT1 expression in 
HCC cells and tissues compared with primary human hepatocytes and 
non-tumorous liver tissue. Furthermore, FAT1 expression correlated 
with higher tumor stage and mitotic activity in human HCCs. These 
Fig. 4. Regulation of FAT1 in HCC cells. (A) Analysis of FAT1 mRNA expression in HCC cells after incubation with control medium (ctrl) and CM of HSCs. 
(B) Analysis of FAT1 mRNA and protein expression after incubation with HGF (50 ng/ml). (C) Effect of anti-HGF antibodies on FAT1 mRNA expression in 
the presence of CM. CM was preincubated with anti-HGF antibodies or isotype-matched control antibodies (ctrl IgG) before addition to HCC cells (*P < 0.05 
compared with ctrl; #P < 0.05 compared with CM). (D) FAT1 mRNA expression in HGF-stimulated cells with or without inhibiting HIF1α with echinomycin 
(Ech). (E) Analysis of FAT1 mRNA expression in HCC cells after pharmaceutical induction of hypoxia by DP. (F) FAT1 and HIF1α protein expression after 
chemical induction of hypoxia by DP. (G) FAT1 mRNA expression with or without pharmaceutical induction of hypoxia and HIF1α inhibition with Ech 
by quantitative PCR. (H) Analysis of FAT1 mRNA after transfection of HCC cells with a dominant-negative variant of HIF1α (dnHIF1α) with or without 
stimulation with DP (*P < 0.05 compared with DP).
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findings indicated that FAT1 acts oncogenic in HCC, and in functional 
studies we identified a protumorigenic effect of FAT1 in HCC cells. 
We observed reduced migratory potential in HCC cells upon FAT1 
suppression in concordance with studies on squamous cell carcinoma 
and glioma cells (9–14). In breast cancer, FAT1 seems to inhibit pro-
gression to an invasive phenotype (47). In cholangiocarcinoma, FAT1 
expression showed an inverse correlation with the proliferation index 
and loss of membranous FAT1 localization correlated with more 
aggressive tumor growth (11). In non-malignant vascular smooth 
muscle cells FAT1 knockdown lead to decreased migratory activity 
but surprisingly and in contrast to our findings in HCC cells enhanced 
proliferation (48). In addition to its varying effects on proliferation 
and migration in different cell types, FAT1 is engaged in several other 
biological functions such as polarity and adhesion or as a regulator 
of inflammatory pathways in cancer cells (49). However, available lit-
erature has not yet functionally linked FAT1 to apoptosis. Here, we 
demonstrate that FAT1 downregulation impairs the resistance of HCC 
cells against induced apoptosis in vitro. Also in vivo tumors derived 
from HCC cells with repressed FAT1 expression revealed significantly 
more apoptosis than tumors derived from control HCC cells. In sum-
mary, our data indicate FAT1 as tumor promotor in HCC. Differently 
than observed in glioblastoma multiforme (14), we did not observe that 
FAT1 affected PDCD4 expression levels or AP-1 activity in HCC cells. 
Currently, we can only speculate on the protumorigenic molecular 
mechanisms set in motion by FAT1 expression in HCC. A most recent 
review by Sadeqzadeh et al. (50) highlights that we are just beginning 
Fig. 5. Mechanisms of FAT1 regulation in HCC. (A) FAT1 mRNA expression in DP-stimulated cells with or without blocking protein synthesis by 
cycloheximide (CHx) (#P < 0.05). (B) Analysis of FAT1 mRNA expression in HCC cells after treatment with different doses of 5-aza-2′deoxycytidine (Aza) 
and adenosine-2′,3′-dialdehyde (Adox) for 48 h (*P < 0.05). (C) SAM level after induction of hypoxia with DP analyzed by liquid chromatography-electrospray 
ionization-tandem mass spectrometry (*P < 0.05). (D) FAT1 mRNA expression in HCC cells stimulated with different doses of SAM and subsequent induction of 
hypoxia with DP for 48 h (*P < 0.05 compared with ctrl; #P < 0.05 compared with DP). (E) Correlation of FAT1 with VEGF and (F) MAT2A mRNA expression 
in HCC tissue (n = 24). (G) Analysis of MAZ and (H) FAT1 mRNA expression in HCC cells transiently transfected with two different MAZ siRNAs (siRNA#1 
and siRNA#2) or control siRNA (ctrl siRNA) and non-transfected control cells (ctrl) (*P < 0.05 compared with ctrl siRNA).
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to understand the molecular interactions of FAT1, which vary in differ-
ent tissues and in health and disease. Future studies have to identify the 
mechanism by which FAT1 exhibits protumorigenic effects in HCC.
In this study we focused on the molecular mechanism responsible 
for the transcriptional upregulation of FAT1 in HCC. Here, we investi-
gated effects mediated by activated HSCs because these cells form and 
infiltrate the HCC stroma and affect HCC development and progres-
sion (16,36,46,51,52). Furthermore, we recently identified activated 
HSCs as the cellular source of increased FAT1 expression in liver fibro-
sis and demonstrated that FAT1 is a profibrogenic factor in these cells 
(17). Due to these profibrogenic effects in HSCs and due to the here 
newly described tumorigenic effects, FAT1 might constitute an excel-
lent therapeutic target in chronic liver disease. Moreover, we found that 
activated HSCs induce FAT1 expression in HCC cells underscoring the 
critical role of activated HSCs in hepatocancerogenesis (16).
Interestingly, activated HSCs induce FAT1 in HCC cells via 
secreted HGF. This multifunctional growth factor and its receptor and 
its high-affinity tyrosine kinase receptor c-MET are critical regula-
tors of HCC development and progression (53). We found that the 
HGF effect on FAT1 activation is mediated via increased activation 
of HIF1α, which plays a critical role in hepatocancerogenesis (38) 
In addition to HGF, hypoxia typically stabilizes HIF1α and herewith 
leads to an activation of this pathway. Hypoxic conditions frequently 
occur in tumorous tissue and are another critical promoter of HCC 
progression (39). Interestingly, we found that HIF1α effects on FAT1 
expression in HCC cells were not mediated directly at the transcrip-
tional level but via reduction of the levels of the methyl donor SAM. 
Liu et al. (42) identified HIF1α-mediated upregulation of MAT2A as 
a novel mechanism, by which hypoxia induces DNA demethylation. 
We confirmed a significant correlation between FAT1 and MAT2A in 
HCC tissues. Together, these findings lead to the following model of 
FAT1 regulation in HCC cells (Supplementary Figure 4, available at 
Carcinogenesis Online): HGF-induced and hypoxia-mediated HIF1α 
activation enhances MAT2A expression and herewith MATII activity. 
As a result MATI activity is reduced, leading to lower levels of the 
methyl donor SAM. Lower SAM levels cause reduced methylation of 
the FAT1 promoter and thereby higher FAT1 expression.
A previous study described the regulatory role of SAM in HGF-
mediated hepatocytes proliferation through a mechanism that impli-
cated the activation of the non-canonical LKB1/AMPK/eNOS 
cascade and the function of human antigen R (HuR), which stabi-
lizes MAT2A mRNA (54). In HCC cells we identified a different 
regulatory pathway by which HGF—and also hypoxia—affected 
SAM levels, and herewith, FAT1 promoter methylation. Thus, this 
study identifies an example how signaling pathways propagated 
from the cell surface through transmembrane receptors to intracel-
lular regulatory mechanisms are critical for normal as well as aber-
rant cellular functions. This knowledge may provide the basis for the 
rational design of novel therapeutics to inhibit HCC development and 
progression.
Supplementary material
Supplementary Figures 1–4 can be found at http://carcin. 
oxfordjournals.org/
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